Recruiting

Observational Study

Sponsor:

Temple University

Code:

NCT07151768

Conditions

Chronic Lung Disease

Pulmonary Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Observational Study

Study Details

Brief summary:

Prospective observational study to determine if the PVD-B65 risk score for one-year mortality in patients with chronic lung disease and pulmonary hypertension (CLD-PH) can accurately risk stratify these patients and successfully predict one-year mortality from time of pulmonary hypertension diagnosis. PVD-B65 risk score was developed in a retrospective cohort of patients with CLD-PH, utilizing the presence of pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) > 5 woods units (WU), 6-minute walk distance (6MWD) < 150 meters, B-natriuretic type peptide (BNP) > 200 pg/mL or N-terminal pro-natriuretic type peptide (NT-proBNP) > 300 pg/dL, and age > 65 years as the score components.

Conditions

Chronic Lung Disease

Pulmonary Hypertension

Study ID

NCT07151768

Start date

Sep 1, 2025

Status verified date

Aug, 2025

Completion date

Sep 1, 2028

Anticipated

Primary completion date

Aug 31, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Eligibility criteria

1. Adult patients ≥ 18 years of age with chronic lung disease diagnosed via CT chest and/or PFT data and pre-capillary pulmonary hypertension diagnosed via right-heart catheterization (RHC, mPAP > 20 mmHg, PVR > 2 WU, and PCWP ≤ 15 mmHg)

1. Chronic lung disease diagnoses will include: COPD, IPF, other pulmonary fibrosis, non-fibrotic ILD, combined pulmonary fibrosis and emphysema, and advanced pulmonary sarcoidosis with parenchymal involvement
2. PFT criteria will include an FEV1/FVC < 0.70 for the diagnosis of COPD
2. Willingness to make return visits and be available by telephone for the duration of the study.
3. Ability to participate in necessary testing, including ambulatory testing

Exclusion Criteria:

  • Exclusion criteria

1. Patients with pulmonary hypertension but without associated chronic lung disease (i.e. idiopathic or group 1 PAH, PH with post-capillary component defined as PCWP > 15 mmHg or group 2 PAH, CTEPH or group 4 PH, group 5 PH aside from sarcoidosis with parenchymal involvement)
2. Patients with uncontrolled severe systemic disease that could influence life expectancy (i.e. uncontrolled cardiovascular disease, active malignancy, etc.)
3. Prior lung and/or heart transplantation

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Interventions

Observational Study

  • assignment of PVD-B65 score derived from standard of care testing
  • no therapeutic intervention or other treatment

Primary outcome measure

  • Prediction of one year mortality [ Time Frame: One year ]

Central Contacts and Locations

Central contacts

Locations

Temple University Hospital

Recruiting

Philadelphia, Pennsylvania, United States, 19140

Contacts

More Information

Sponsor

Temple University

Last update posted

Sep 3, 2025

Last verified

Aug, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Temple University on 2025-09-03.